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CASE REPORT
We describe here a patient who obtained a good analgesic effect with high-dose fentanyl patches for controlling
cancer pain. A 52-year-old man was referred to our hospital because of severe cancer pain that was 7/10 on a
numeric rating scale (NRS). He had been diagnosed with locally advanced cholangiocarcinoma 3 months
previously. We prescribed weak opioids and an antidepressant, but his pain was not relieved. We introduced
strong opioids (transdermal fentanyl patches for the background pain and a short-acting opioid for the
breakthrough pain) and his pain was tolerable on 250 µg/hr of fentanyl patches for 3 months. With time, however,
his pain intensity became worse and this reached up to 8/10 to 9/10 on the NRS. Percutaneous transhepatic
biliary drainage was performed, which did not relieve his pain. We increased gradually the dose of transdermal
fentanyl to 1,050 µg/hr (20 patches). At this dose, the patient was mentally alert, with good pain control (NRS 2/10
to 3/10) and no exacerbation of side effects. To the best of our knowledge, we report here on the highest dose of
transdermal fentanyl that has been successfully used for treating a patient suffering from visceral cancer pain.
(Korean J Intern Med 2010;25:337-340)
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INTRODUCTION
The high prevalence of pain in patients suffering with
terminal cancer is well documented. Management of
cancer pain is one of the most important goals of palliative
care. Opioid narcotics are the cornerstone drugs for
managing severe cancer pain, with or without adjuvant
drugs. Fentanyl is a synthetic opioid-agonist that primarily
interacts with the mu-opioid receptor. Transdermal fentanyl
patches are designed to deliver fentanyl at a constant rate
from a reservoir [1]. There have been many studies on the
efficacy and convenience of transdermal fentanyl patches
for controlling both cancer pain and non-cancer pain [2-
4]. Compared with other opioids, fentanyl patches have
been associated with better pain relief, less constipation
and they enhance the quality of life [4]. Especially, these
patches are a good choice for patients with dysphagia,
changes of consciousness and those who need opioid
rotation due to side effects [5]. 
Although it is well known that there is no upper dose
limit when using opioids, high doses of opioids are
commonly feared by physicians, patients and caregivers
[6,7]. Therefore, treatment for the pain of patients with
terminal cancer is often inadequate. We describe here a
patient with advanced cholangiocarcinoma who obtained
a good pain control with high doses of transdermal
fentanyl for cancer pain.
CASE REPORT
A 52-year-old man was referred to our hospital because
of cancer pain that was 4/10 to 5/10 on a numeric rating
scale (NRS). Three months previously, he had been338 The Korean Journal of Internal Medicine Vol. 25, No. 3, September 2010
diagnosed with locally advanced cholangiocarcinoma
at other hospital (Fig. 1A) and he had been treated by
concurrent chemoradiotherapy with no response. He was
taking non-steroidal anti-inflammatory drugs due to
his mild abdominal pain. However, the cancer pain was
aggravated as his cancer progressed. His pain was mainly
dull, being located in the right upper quadrant of the
abdomen. The cancer pain diminished his appetite and it
often woke him from sleeping at night. We initially
prescribed tramadol (300 mg/day) and amitriptyline (10
mg/day), but his background pain was not effectively
relieved. Thus, we administered transdermal fentanyl
patches (12.5 µg/hr) for the background pain and oxycodone
immediate release (OIR) tablets for the breakthrough
pain, and this treatment brought a dramatic improvement
of his pain. Yet after 10 days, the background pain was
abruptly aggravated (6/10 on the NRS). The dose of
fentanyl was gradually increased to 250 µg/hr over 2
months and his pain became tolerable (2/10 on NRS). 
After about 4 weeks on this dose of fentanyl patch, his
pain intensity became worse and it eventually reached up
to 8/10 to 9/10 on NRS. On admission, we added oxycodone
(20 to 200 mg/day) and increased the dose of amitriptyline
to 40 mg/day, but the patient failed to obtain an analgesic
effect. Abdominal CT was done to find any unknown pain-
relieving factors at that time, and the CT showed a severe
intrahepatic ductal dilatation (Fig. 1B). Percutaneous
transhepatic biliary drainage was performed at once,
which did not relieve his pain. Thereafter, he refused all
invasive procedures, including celiac plexus block or
epidural block. We discontinued oxycodone and increased
the dose of fentanyl patch over 3 weeks. In the 2 weeks
before the patient’s death, the dose of transdermal fentanyl
reached 1,050 µg/hr (Fig. 2). At this dose level, the patient
obtained a good pain control (NRS 2/10 to 3/10) with
no exacerbation of side effects. He was able to walk
independently and sleep well without interruption.   
DISCUSSION
Cancer pain affects most patients with advanced
malignant disease. The prompt recognition of cancer
pain allows implementation of effective palliative care.
Although most cancer pain can be relieved, effectively
controlling the pain of cancer patients is often problematic.
One of the reasons for this is related to the so-called
opioidphobia by physicians, patients and caregivers [6,7].
Many clinicians are afraid that high-dose opioids may lead
to respiratory depression and hasten the death of patients.
However, studies describing the morphine dosage used
for hospice patients demonstrated that high-dose
morphine has a high safety profile and it doesn’t adversely
affect the survival of the patients [8,9]. 
For our case reported here, we mostly applied transdermal
fentanyl patches for the cancer pain. We initially administered
a 12.5 µg/hr fentanyl patch for background pain that was
4/10 to 5/10 on the NRS, which brought about dramatic
pain control. With time, however, the patient’s cancer pain
was aggravated and the dose of transdermal fentanyl was
gradually increased to 250 µg/hr. When the patient’s pain
intensity became worse (8/10 to 9/10 on NRS) in spite of
Figure 1. Abdominal computed tomography (CT) scans with contrast. (A) The initial CT scan revealed a mass with slightly dilated
intrahepatic bile ducts in the right lobe of the liver. (B) Follow-up CT showed an increased size of the mass along with severe intrahepatic
ductal dilatation.
A Bbeing on 250 µg/hr transdermal fentanyl, we added
oxycodone tablets. Several preliminary data suggested
that partial opioid rotation and opioid combinations may
be beneficial for patients with a poor analgesic effect after
dose escalation [10]. Yet for our patient, adding the second
opioid failed to achieve a good analgesic effect. 
The highest dose of transdermal fentanyl reported in
the English medical literature was 3,400 µg/hr (34 patches
of 100 µg/hr each), which used for a 58-year-old woman
with neuropathic pain due to a Pancoast tumor of the lung
[11]. However, this huge dose had no effect for relieving
her from neuropathic pain. In our patient, we increased
the dose of transdermal fentanyl to 1,050 µg/hr (21 patches
of 50 µg/hr each) over 3 weeks after discontinuing the
oxycodone. At this dose, the patient could obtain good
pain control during the last 2 weeks of his life, with no
exacerbation of side effects. 
To the best of our knowledge, we have reported here
on the highest dose of transdemal fentanyl that was
successfully used for a patient suffering from visceral
cancer pain. The administered fentanyl dose was
equianalgesic to about a 4,000 mg dose of oral morphine/
24 hours. Our experience suggests that if it is needed for
controlling cancer pain, administering high-doses of
opioids should not be feared. However, orally administering
this dose of opioids inevitably requires a large amount of
tablets to be taken daily, which may induce more side
effects and make patients uncomfortable. Therefore, high
doses of fentanyl patches may be a good choice for those
patients who need a megadose of opioids to control their
cancer pain. 
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